Cargando…

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

SIMPLE SUMMARY: Melanoma accounts for only 4% of skin cancer, but is the major cause of skin cancer related deaths. The use of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor), two FDA approved drugs to treat patients with BRAFV600E melanoma, is limited in the clinic due to the development...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Hima, Mishra, Rosalin, Yacoub, Nour, Alanazi, Samar, Kilroy, Mary Kate, Garrett, Joan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616282/ https://www.ncbi.nlm.nih.gov/pubmed/34831014 http://dx.doi.org/10.3390/cancers13225863

Ejemplares similares

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
por: Yuan, Long, et al.
Publicado: (2020)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023)

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
por: Mishra, Rosalin, et al.
Publicado: (2021)

Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma
por: Yuan, Long, et al.
Publicado: (2018)

HER3 Alterations in Cancer and Potential Clinical Implications
por: Kilroy, Mary Kate, et al.
Publicado: (2022)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers
por: Alanazi, Samar M., et al.
Publicado: (2023)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

HER3 signaling and targeted therapy in cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
por: Mazor, Roei D, et al.
Publicado: (2020)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)
por: Tarhini, A.A., et al.
Publicado: (2021)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
por: Zhang, Simeng, et al.
Publicado: (2023)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
por: Byron, Sara A, et al.
Publicado: (2012)

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
por: Loria, Rossella, et al.
Publicado: (2022)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder
por: Yu, Zhou, et al.
Publicado: (2018)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_08n9b42k6someblbrl53laq03l